Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man

doi:10.1016/0049-3848(85)90116-1

Thrombosis Research

Volume 39, Issue 1, 1 July 1985, Pages 1-8

https://doi.org/10.1016/0049-3848(85)90116-1 Get rights and content

Abstract

The effects on fibrinolysis of purified normal human plasma lipoproteins and their apolipoproteins (apo) were assessed in an in vitro system containing urokinase, plasminogen, and fibrin. High and very low density lipoproteins (HDL and VLDL, respectively) but not low density lipoproteins (LDL) significantly increased lysis of radiolabeled fibrin or lysis area of plated fibrin compared to controls. Apo HDL, apo HDL₂, apo HDL₃, apo VLDL (buffer soluble apo), apo AI and AII activated fibrinolysis by 1.3 – 1.4 fold of control values, whereas apo B (as a narrow density cut of LDL) and non-lipoprotein control proteins (albumin and myoglobin) did not. Addition of HDL in the absence of urokinase failed to activate fibrin lysis. These data demonstrate that the major proteins of HDL — apo AI and apo AII — and possibly certain minor constituent(s) common to HDL and VLDL participate in the fibrinolytic process.

References (15)

M.L. Kashyap et al.
Effects of dietary carbohydrate and fat on plasma lipoproteins and apo lipoproteins C-II and C-III in healthy men
J. Lipid Res.
(1982)
O.H. Lowry et al.
Protein measurement with the folin phenol reagent
J. Biol. Chem.
(1951)
M.L. Kashyap et al.
A rapid and simple method for measurement of total protein in very low density lipoproteins by the Lowry assay
J. Lipid Res.
(1980)
J.C.H. Steele
The effect of plasmin on human plasma low density lipoprotein
Thromb. Res.
(1979)
H.R. Lijnen et al.
Degradation of the apoprotein A-I polypeptide chain of human high density lipoprotein by human plasmin
Thromb. Res.
(1981)
K. Saku et al.
C-II anapolipoproteinemia and severe hypertriglyceridemia
Am. J. Med.
(1984)
A Nordoy et al.
The effect of lipoproteins on the synthesis of prostacyclin, Von Wellebrand factor and apolipoproteins A-I and A-II in cultured human endothelial cells
Atherosclerosis
(1984)

There are more references available in the full text version of this article.

Cited by (117)

Degenerated HDL and Its Clinical Implications
2017, The HDL Handbook: Biological Functions and Clinical Implications: Third Edition
High-density lipoprotein (HDL) has several potential antiatherogenic effects and protective effects on endothelial cells. Therefore abnormal and reduced vasoprotective effects of HDL are closely associated with atherogenesis and an increased risk of cardiovascular disease. Oxidative modifications have been proposed for alteration and deterioration of HDL. The oxidation of HDL particles is likely to have important consequences not only for cholesterol homeostasis in peripheral tissues but also for the development of vascular diseases associated with oxidative stress. This chapter reviews current literature regarding structural and functional changes in HDL induced by oxidation and discusses the clinical relevance of oxidized HDL to atherogenic events.
Exploring the impact of bariatric surgery on high density lipoprotein
2015, Surgery for Obesity and Related Diseases
Low HDL cholesterol is an independent cardiac risk factor. A general efficacy gradient exists for the resolution of cardiovascular risk factors after bariatric surgery (i.e., biliopancreatic diversion [BPD]>Roux-en-Y gastric bypass [RYGB]>sleeve gastrectomy [SG]>adjustable gastric banding [AGB]). However, a review of high level of evidence clinical studies shows a different hierarchy for the effect of bariatric surgery on HDL (i.e., RYGB = SG>BPD, AGB). Surgically induced weight loss effectively reverses many steps in HDL metabolism that have been altered with obesity. Furthermore, enterocytes contribute to HDL levels through the synthesis of apolipoproteins A-IV and A-I. RYGB and SG that preserve the small intestine (particularly the jejunum) lead to a significant rise in HDL. However, when the small intestinal contribution does not reinforce the weight loss dependent mechanisms (e.g., after BPD and AGB), only a modest rise in HDL occurs. Further experimental and clinical studies are required to better delineate the issue.
Oxidized High-Density Lipoprotein: Friend or Foe
2014, The HDL Handbook: Biological Functions and Clinical Implications: Second Edition
High-density lipoprotein (HDL) is considered to be a major anti-atherogenic particle that inhibits conversion of low-density lipoprotein (LDL) into its oxidized form (oxLDL), reduction in the vasoregulatory function, and formation of foam cells. In in vitro experiments, the HDL particle is found to be more vulnerable to oxidative modification than LDL. In addition, recent attentive investigations of clinical specimens have shown that HDL from coronary artery disease and dyslipidemia subjects has a higher sensitivity to lipid oxidation, and that levels of plasma-oxidized HDL (oxHDL) in patients with atherosclerosis, diabetes mellitus, and renal failure are significantly higher, compared with those from healthy donors. Numerous studies using potential oxidants moreover suggest that the oxidative modification of HDL reduces its intrinsic beneficial properties, such as reverse cholesterol transport and antioxidant property, and progressively participates in the development of atherosclerosis through appearance of the pro-inflammatory and cytotoxic effects. By contrast, we recently found that 4-hydroxy-2-nonenal, which is generated during oxidation of HDL, induces cross-linking of apoproteins and upregulates antioxidant enzymes such as aldo-keto reductase (AKR) 1C1 and AKR1C3. In this chapter, we introduce the current literature on clinical relevance of oxHDL to vascular-related diseases, and the structural and functional alterations in HDL due to treating with oxidants. In addition, on the basis of the oxidation-elicited functional changes in HDL and cellular responses to the oxHDL treatment, we discuss whether oxHDL is a causal factor, like oxLDL, or a protective factor for the development of atherosclerosis.
Association of high-density lipoprotein cholesterol with coronary heart disease risk across categories of low-density lipoprotein cholesterol: The atherosclerosis risk in communities study
2011, American Journal of the Medical Sciences
Citation Excerpt :
Although future trials will ultimately determine the benefit of cholesterol ester transport protein inhibitors, HDL-cholesterol has also been proposed to have other antiatherosclerosis properties. These include being an antioxidant, anti-inflammatory, nitric oxide promoter and platelet inhibitor.31–34 In Cox proportional hazards models including adjustment for LDL-cholesterol, each SD higher HDL-cholesterol (18 mg/dL) was associated with a 0.70 (95% CI: 0.63-0.77) risk of CHD.
National cholesterol treatment guidelines include a low level of high-density lipoprotein (HDL) cholesterol (< 40 mg/dL) as a major risk factor for coronary heart disease (CHD) that should be considered when making decisions on treatment of low- density lipoprotein (LDL) cholesterol.
We investigated the association of HDL and LDL-cholesterol with incident CHD events (fatal or nonfatal CHD) over 14 years of follow-up among 13,615 adults aged 45 to 64 years in the Atherosclerosis Risk in Communities study.
A total of 966 (7.1%) participants had a CHD event during follow-up. After adjustment for age, race, sex, diabetes, smoking, alcohol consumption, systolic blood pressure, waist circumference, chronic kidney disease and physical activity, a graded association was present between progressively lower levels of HDL-cholesterol and higher CHD risk, overall (P < 0.001) and within each level of LDL-cholesterol (< 100, 100–129, 130–159, 160–189 and ≥ 190 mg/ dL) investigated (all P < 0.05). In addition, after multivariable adjustment including LDL-cholesterol, each standard deviation higher HDL- cholesterol (18 mg/dL) was associated with a hazard ratio of incident CHD of 0.70 (95% Cl: 0.63–0.77).
These data suggest a graded association exists between lower levels of HDL-cholesterol and CHD across the full range of LDL-cholesterol levels. As interventions targeting HDL levels are developed, the combinatorial effects of lower HDL levels with various levels of LDL-cholesterol should be examined.
High-density lipoproteins: Marker of cardiovascular risk and therapeutic target
2010, Journal of Clinical Lipidology
Citation Excerpt :
HDL can stimulate increased endothelial nitric oxide synthase and nitric oxide expression and induce vasodilation.65–67 HDL can also inhibit endothelial cell apoptosis68 and adhesion molecule expression,69 inhibit platelet activation and aggregation,70 can participate in immunity by carrying complement proteins,48 and stimulate urokinase dependent fibrinolysis71 and prostacyclin production by activating cyclooxygenase-2,72 among other functions. HDL carries a number of antioxidative enzymes (paraoxonase, platelet activating factor acetylhydrolase, glutathione peroxidase, and two redox active methionine centers in apoAI) that can facilitate the reduction and sequestration of oxidized lipid in LDL particles.73–77
The high-density lipoproteins (HDLs) are complex, polymolecular assemblies produced by the jejunum, liver, in serum, and on the surface of macrophages. HDL cholesterol (HDL-C) levels are an independent predictor of risk for cardiovascular events in both men and women. High serum levels of this lipoprotein are associated with reduced risk for atherosclerosis and its clinical sequelae, such as myocardial infarction, ischemic stroke, and death. The molecular basis for the apparent vasculoprotection afforded by elevated HDL-C is widely attributed to the ability of HDL particles to drive reverse cholesterol transport. The proteosome (protein cargo) of HDL also appears to endow this lipoprotein with a capacity to reduce oxidized lipids, promote endothelial cell nitric oxide production, reduce adhesion molecule expression, inhibit platelet activation, stimulate endothelial proliferation and inhibit apoptosis, and reduce inflammatory mediator expression, among other functions. Recent investigation suggests that among patients with coronary artery disease, HDL can also be dysfunctional, yielding a pro-inflammatory and pro-oxidative phenotype. Numerous drugs are currently in development in an effort to devise the means by which to optimally increase serum levels of functional, antiatherogenic HDL species. These drugs exploit a diverse range of mechanisms with potential for beneficially impacting the development and progression of atherosclerotic disease.
Functional Change in the HDL Particle by Oxidative Modification and its Contribution to Atherogenesis
2010, The HDL Handbook: Biological Functions and Clinical Implications
This chapter focuses on the functional change in the high density lipoprotein (HDL) particle by oxidative modification and its contribution to atherogenesis. HDL contains antioxidant molecules and enzymes in the particle, which oxidizes more rapidly than low density lipoprotein (LDL) during in vitro oxidation. This suggests a possibility that oxidized lipoproteins, including both HDL and LDL, are involved in the genesis of coronary artery diseases and reflect an oxidative stress state of the diseases. Myeloperoxidase, an enzyme in macrophages and neutrophils, may be one of the most potential enzymes concerning in vivo oxidant generation. This enzyme system generates reactive species including hypochlorous acid/hypochlorite, tyrosyl radicals, chloramines, and nitrogen dioxides. Lipoxygenase, which is produced by endothelial cells and macrophages, may also participate in the in vivo oxidation of lipoproteins, because treatment with the enzyme inhibitors prevents cell-mediated oxidation of LDL. The oxidative mechanism of lipoproteins by lipoxygenase is mediated by conversion of polyunsaturated fatty acids into lipid peroxides including 13S-hydroxy-9, 11-octadecadienoic acid, and the metabolites are detected in the early stage of atherosclerosis. Peroxynitrite can directly oxidize polyunsaturated fatty acids, tocopherols, carbohydrates, DNA, and proteins. Functional alterations in HDL by oxidation result in reverse cholesterol transport, reduction of cholesterol efflux, reduction of cholesterol esterification, disruption of cholesterol homeostasis, reduction of antioxidant activity, decrease in nitric oxide production and its function, induction of pro-inflammatory effect, increase in expression of plasminogen activator inhibitor, and induction of cytotoxic effect.

View all citing articles on Scopus

View full text

PaperActivation of fibrinolysis by apolipoproteins of high density lipoproteins in man

Abstract

J. Lipid Res.

J. Biol. Chem.

J. Lipid Res.

Thromb. Res.

Thromb. Res.

Am. J. Med.

Atherosclerosis

Paper
Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man